Categoria: Abstract

Background Choosing the adequate systemic treatment for melanoma is driven by clinical parameters and personal preferences. Objective Evaluation of the impact of disease and treatment on the daily life of patients receiving systemic therapy for melanoma. Methods A German-wide, cross-sectional comparative study was conducted at 13 specialized skin cancer centres from 08/2020 to 03/2021. A...

Background The objective of this study was to estimate the relative efficacy and safety of targeted therapies for the treatment of metastatic melanoma using a network meta-analysis (NMA). Methods A systematic literature review (SLR) identified studies in Medline, Embase and Cochrane published until November 2020. Screening used prespecified eligibility criteria. Following a transitivity assessment across...

Background Primary analysis of the phase 3 IMspire150 study showed improved investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) versus placebo, vemurafenib, and cobimetinib (control group) in patients with BRAFV600 mutation-positive melanoma. With a median follow-up of 18·9 months (IQR 10·4-23·8) at the primary analysis, overall survival data were immature. Here, we...

Importance A key issue for the adjuvant treatment of patients with melanoma is the assessment of the effect of treatment on relapse, survival, and quality of life (QOL). Objective To compare QOL in patients with resected melanoma at high risk for relapse who were treated with adjuvant pembrolizumab vs standard of care with either ipilimumab...

Background New immunotherapy and targeted therapy options have recently shown significant recurrence-free survival (RFS) improvements when offered to patients (pts) with Stage (St) II-III melanoma in the ADJ setting. Our study aims to evaluate anti-PD-1 antibodies and BRAF-MEK inhibitors efficacy and safety in terms of NNT and NNH calculated from respective phase III trials. Material...

Background Checkpoint inhibitors immunotherapy (CII) has significantly improved the treatment landscape for MM with a significant proportion of them obtaining long-lasting and deep responses. Despite these results, over half of patients present primary or acquired resistance to treatment. Among the currently unmet needs, there is a lack of predictive biomarkers able to identify non-responders or...

Background D+T combination therapy is one of the recommended options in 1L treatment for pts with BRAFV600-mutant metastatic melanoma. However, limited data are available on the patterns of disease progression and the impact of the D+T combination on the clinical outcomes of subsequent treatment lines in a real-world setting. Methods: This multicenter, prospective, non-interventional study...

Background Mismatch repair deficit (dMMR) and microsatellite instability (MSI) have been reported in skin melanoma and are thought to be a progression dependent phenomenon seen in thicker primary lesions and metastases. Few studies on frequency, predictive and prognostic value of MSI in melanoma are available, in particular using the pentaplex panel of markers approved for...

Background Elderly patients represent a peculiar setting for cancer therapy, with specific characteristics mostly in terms of comorbidities and concomitant therapies. Therefore, the optimal therapeutic strategy for elderly patients represents an intriguing clinical challenge. In pivotal clinical trials older patients are underrepresented but real-world data showed that outcomes are similar to that of the younger...

Background Adjuvant therapy has shown improvement in the outcome of patients with resected stage III melanoma, reducing the risk of recurrence by elimination of residual disease after surgery. Since receiving approval from European Medicines Agency (EMA) in 2018, dabrafenib + trametinib (D+T) has been the only targeted therapy available for adjuvant systemic treatment in patients...